AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
VaxGen Awarded Second NIH Grant To Develop AIDS Vaccine.(Brief Article)
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- VaxGen Inc. has been awarded the second part of a $1.1 million grant from the National Institutes of Health (NIH) to continue the development of a vaccine designed to prevent infection by HIV subtype C, the most widespread form of the virus. Subtype C is estimated to be responsible for approximately half of the world's 36 million infections and is the most common subtype found in southern Africa, India, and China.
The Small Business Innovation Research fast track grant provides up to $981,000 for the development program and is in addition to $150,000 that VaxGen received earlier this year through the first part of the grant.
"This new NIH grant will allow VaxGen to create and conduct laboratory tests of a subtype C vaccine that could be used alone in southern Africa and India, or could be combined with a vaccine against the B and E subtypes for regions of the world such as China, where all three subtypes are in circulation," said Phillip Berman, PhD, ...
- VaxGen Awarded Second NIH Grant for Development of AIDS Vaccine for Africa,...
- Press release article from: PR Newswire October 3, 2001 700+ words
...to $150,000 that VaxGen received earlier this...the grant. "This new NIH grant will allow VaxGen to create and conduct...term of two years, VaxGen will select the best...second phase of the NIH grant provides approximately...
- VaxGen Awarded Second NIH Grant To Develop AIDS Vaccine.(Brief Article)
- Newspaper article from: AIDS Weekly November 12, 2001 700+ words
...to $150,000 that VaxGen received earlier this...the grant. "This new NIH grant will allow VaxGen to create and conduct...term of two years, VaxGen will select the best...second phase of the NIH grant provides approximately...
- VaxGen Awarded NIAID/NIH Grant to Identify Novel Antigens for Possible New HIV...
- Press release article from: PR Newswire June 10, 2003 700+ words
VaxGen today announced that it was awarded a phase...and is in addition to the $210,000 that VaxGen received late last year through phase 1...grant comes less than four months after VaxGen announced preliminary results from the world...
- VaxGen to Hold Conference Call to Address Misconceptions Over Government's AIDS...
- Press release article from: PR Newswire February 26, 2002 700+ words
BRISBANE, Calif. -- VaxGen, Inc. will host a conference call...Phase III trial that would have combined VaxGen's AIDS vaccine with another experimental...P. Francis, M.D., D.Sc., VaxGen president, will explain that the decision...
- VaxGen and BD to Jointly Evaluate Novel Dermal Injection Technology for...
- Press release article from: PR Newswire February 21, 2006 700+ words
...Feb. 21 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN.PK) announced...Micro Injection technology to deliver VaxGen's recombinant anthrax vaccine candidate...administration (injection into the skin) of VaxGen's anthrax vaccine with the patented...
- VaxGen to Present Update at SG Cowen Conference; Company to Increase Cash and...
- Press release article from: PR Newswire March 13, 2003 700+ words
...PRNewswire-FirstCall/ -- WHAT: VaxGen CEO Lance K. Gordon, Ph.D., will...and revenue from grants and contracts. VaxGen expects total cash, which is composed...include $18 million in available cash that VaxGen had as of Dec. 31, 2002. (Photo...
- VaxGen Restructures Following Termination of Proposed Merger.
- Press release article from: PR Newswire April 9, 2008 700+ words
...April 9, 2008 /PRNewswire-FirstCall/ -- VaxGen, Inc. (BULLETIN BOARD: VXGN) , a biopharmaceutical...the termination of the proposed merger between VaxGen and Raven biotechnologies, inc. VaxGen has moved to terminate the staff which it had...
- VaxGen Provides Update on Financial Reaudit; Company Believes Process Will...
- Press release article from: PR Newswire December 14, 2004 700+ words
VaxGen, Inc. (Pink Sheets: VXGN) provided...financial statements. As previously announced, VaxGen and its independent auditors have been reauditing...fixed-price contract recently awarded to VaxGen for the purchase of 75 million doses of...